<code id='5DDA4A445B'></code><style id='5DDA4A445B'></style>
    • <acronym id='5DDA4A445B'></acronym>
      <center id='5DDA4A445B'><center id='5DDA4A445B'><tfoot id='5DDA4A445B'></tfoot></center><abbr id='5DDA4A445B'><dir id='5DDA4A445B'><tfoot id='5DDA4A445B'></tfoot><noframes id='5DDA4A445B'>

    • <optgroup id='5DDA4A445B'><strike id='5DDA4A445B'><sup id='5DDA4A445B'></sup></strike><code id='5DDA4A445B'></code></optgroup>
        1. <b id='5DDA4A445B'><label id='5DDA4A445B'><select id='5DDA4A445B'><dt id='5DDA4A445B'><span id='5DDA4A445B'></span></dt></select></label></b><u id='5DDA4A445B'></u>
          <i id='5DDA4A445B'><strike id='5DDA4A445B'><tt id='5DDA4A445B'><pre id='5DDA4A445B'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:99
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator
          Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

          Hevolution'sexecutiveteamincludes,fromleft,SophiaPathai,HayaBintKhaledBinBandarAlSaud,MehmoodKhan,an

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo